David Douglass Joins NeuroMetrix Board of Directors.

CAMBRIDGE, Mass.--(BW HealthWire)--Jan. 22, 1999--NeuroMetrix, Inc., a developer of medical devices for the diagnosis of neuromuscular diseases, announced today that David Douglass of Delphi Ventures has joined its Board of Directors.

"David brings a wealth of experience in the medical products industry that will be a valuable asset to the Company", said Richard J. Thomas, President. "He has been directly involved in the success of many device and diagnostic companies, and we will clearly benefit from his contributions to the Board. On a personal level, I have known David for several years, and I am looking forward to working closely with him at NeuroMetrix."

"The skills and experiences of our outside directors complement each other to provide invaluable guidance to the management team," said Shai N. Gozani, M.D. Ph.D., Chairman & CEO. "The Company has benefited immeasurably from their contributions, and the addition of David will only strengthen the Board even further."

David Douglass is a General Partner at Delphi Ventures where he has focused primarily on medical device and service companies. Prior to joining Delphi, he was a General Partner at Matrix Partners. He had previously served as Chief Operating Officer at Paladin Software Corporation, as Vice President of Finance and Administration at Collagen Corporation and as a consultant to McKinsey & Company. Mr. Douglass received a B.A. from Amherst College and earned a M.B.A. and M.A. from Stanford University.

Mr. Douglass joins current investors Charles Harris, of Harris & Harris Group, and William Laverack, of J. H. Whitney & Co., as well as Dr. Gerald Fischbach, Director of the National Institute for Neurological Disorders and Stroke, on the NeuroMetrix Board of Directors. Dr. Gozani and Mr. Thomas are also Directors of the Company.

NeuroMetrix, Inc., a development stage company located in Cambridge, MA, is a spin-off from the Harvard-M.I.T. Division of Health Sciences and Technology. Based on advances in neuroscience and microelectronics, NeuroMetrix is developing a new class of non-invasive products for point-of-care testing of neuromuscular disorders. The Company anticipates that its technology will provide physicians with immediate and cost-effective information to be used as an aid in the diagnosis of common neuromuscular conditions including repetitive stress injuries, peripheral and toxic neuropathies and low back pain.